# Allopurinol in Acute Coronary Syndrome

Study · id `cardio:ct-nct03745729` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03745729](<https://clinicaltrials.gov/study/NCT03745729>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03745729

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 162 participants.

## Technical summary

Registry record NCT03745729. Randomized; double masking; primary purpose treatment. Start 2019-03-01 (actual); primary completion 2022-07-15 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 162 participants (enrolled count; ClinicalTrials.gov record NCT03745729, source copy `cardio:ctgov-nct03745729-2022-09-16`, retrieved 2026-10-31)
- Started: 2019-03-01 (actual) (ClinicalTrials.gov record NCT03745729, source copy `cardio:ctgov-nct03745729-2022-09-16`, retrieved 2026-10-31)
- Primary completion: 2022-07-15 (actual) (ClinicalTrials.gov record NCT03745729, source copy `cardio:ctgov-nct03745729-2022-09-16`, retrieved 2026-10-31)
- Completion: 2022-07-15 (actual) (ClinicalTrials.gov record NCT03745729, source copy `cardio:ctgov-nct03745729-2022-09-16`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT03745729, source copy `cardio:ctgov-nct03745729-2022-09-16`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03745729-2022-09-16`, retrieved 2026-10-31)

## The registry's words

- Brief title: Allopurinol in Acute Coronary Syndrome
- Condition: Acute Coronary Syndrome
- Intervention (Drug): allopurinol sustained-release capsules
- Intervention (Drug): placebo capsules
- Lead sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry lists this organization as the lead sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (`cardio:org-union-hospital-tongji-medical-college-huazhong-university-090806`)

## Provenance

Content hash: 48e6099b9a32100d39b2f948a6023fbcf3bb5c5b4054b2f6dee82913ddbd864b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
